Advertisement

Topics

Search Results for "Brilinta Sales"

16:59 EDT 23rd October 2017 | BioPortfolio

Matching Channels

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Sales Jobs

GE Healthcare

Ranked as the third largest medical device company in the world (based on annual sales), GE Healthcare generates $16 billion in sales each year. GEs' area of expertise is the imaging that is i...

Siemens

Siemens Healthcare is the second largest medical devices company in the world (based on annual sales), with sales of $17.4 billion. Specializing in the imaging, IT, diagnostics and workflow soluti...

Medtronic

With annual sales reaching $15 billion in 2010, Medtronic is the 4th largest medical devices company in the world (based on annual sales). The device portfolio of Medtronic is broad; covering card...

Matching News

Extended use of AstraZeneca's Brilinta reduces cardiovascular death risk

New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk of heart attacks by almost a third in patients with a history of such atheroth...

Extended use of AZ’ Brilinta cuts CV death risk 29%

Long-term use of AstraZeneca’s Brilinta in patients with a history of heart attack reduces the risk of cardiovascular death by 29 percent, a new sub analysis of data from the Phase III PEGASUS-T...

New heart attack data boost AZ’s Brilinta

A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients. The new study will be presented at the European Soci...

AZ withdraws Brilinta batch for containing the wrong drug after packaging mix-up

The United Arab Emirates Ministry of Health and Prevention has called for the withdrawal of a batch of AstraZeneca’s cardiovascular drug Brilinta (ticagrelor) 90mg with immediate effect, after it wa...

AstraZeneca's Brilinta protects against adverse cardiovasular events for up to 5 years, new data reveals

AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the treatment proved able to provide continued and consistent...

AstraZeneca's Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals

AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the treatment proved able to provide continued and consistent...

Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) from treatment with Brilinta (tic...

AstraZeneca PLC's Brilinta Cuts Repeat Heart Attack Risk by Almost a Third

  Life Sciences Jobs   ...

Matching PubMed Articles

Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.

To determine the prevalence of nonprescription naloxone and sterile syringe sales, factors associated with nonprescription sales, geospatial access to nonprescription naloxone and syringe-selling phar...

Policy coherence, integration, and proportionality in tobacco control: Should tobacco sales be limited to government outlets?

Multiple factors, including marijuana decriminalization/legalization, tobacco endgame discourse, and alcohol industry pressures, suggest that the retail regulatory environment for psychoactive or addi...

Impact of CVS Pharmacy's Discontinuance of Tobacco Sales on Cigarette Purchasing (2012-2014).

To assess the impact of CVS Health's discontinuation of tobacco sales on cigarette purchasing.

Drawing the Line.

Politicians have long touted giving consumers the ability to buy health insurance across state lines as part of health care reform. Several states have passed laws of their own allowing interstate sal...

Trends in Sales of Flavored and Menthol Tobacco Products in the United States during 2011-2015.

Flavors can mask the harshness of tobacco and make it appealing to young people. This study assessed flavored and menthol tobacco product sales at the national and state levels.

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement